Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib Maintenance in FLT3/ITD AML CR1
NCT02927262Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Jan 2017
- Primary completion
- May 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 21
01
Overview
Phase 2, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Gilteritinib with Placebo (2 arms). Primary endpoint: Relapse-free Survival up to 2 years. Started Jan 2017; status: completed.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02927262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02927262.